Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs
Home
About Us
Management Team
Board of Directors
Investors
Pipeline
Pipeline Overview
Intermezzo
®
TO-2060
News & Events
Press Releases
Press Release Archive
Events
Careers
Contact Us
News & Events
04/15/08
Study of Intermezzo® by Leading Sleep Expert Published in "Human Psychopharmacology"
03/19/08
Transcept Pharmaceuticals to Present at "Future Leaders in the Biotech Industry" Conference
Learn More About Our Pipeline
Intermezzo
®
(zolpidem tartrate sublingual lozenge)
Phase 3 clinical trials have completed for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep.
Learn More
TO-2060
A novel fixed combination dose of olanzapine and ondansetron being evaluated for the treatment of dopamine associated psychiatric disorders.
Learn More